1-4 of 4
Lin-Chi Chen
Close
Sort by
Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 813.
https://doi.org/10.1182/blood.V130.Suppl_1.813.813
Published: 2017
Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD
Journal: Blood
Blood (2016) 128 (22): 2843.
https://doi.org/10.1182/blood.V128.22.2843.2843
Published: 2016
Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Bernhard Reis, PhD, Lori Jukofsky, Gong Chen, PhD, Giovanni Martinelli, Hua Zhong, PhD, Venus So, PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Mark W. Drummond, PhDMD, Sarit E. Assouline, MDMSc, Maneja Hashemyan, Michel Theron, PhD, Steven Blotner, PhD, Je-Hwan Lee, MD PhD, Margaret Kasner, MD, Sung-Soo Yoon, Ruediger Rueger, MD, Karen Seiter, MD, Steven Middleton, PhD, Kevin R. Kelly, MD, PhD, Norbert Vey, Karen W.L. Yee, MD, Gwen Nichols, MD, Lin-Chi Chen, MD PhD, William E. Pierceall, PhD
Journal: Blood
Blood (2015) 126 (23): 2580.
https://doi.org/10.1182/blood.V126.23.2580.2580
Published: 2015
Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Karen Yee, MD, Giovanni Martinelli, MD, Norbert Vey, MDPhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Karen Seiter, MD, Sarit Assouline, MD MSc, Mark Drummond, MD PhD, Sung-Soo Yoon, MDPhD, Margaret Kasner, MD, Je-Hwan Lee, MD PhD, Kevin R. Kelly, MD PhD, Steven Blotner, PhD, Brian Higgins, Steven Middleton, PhD, Gwen Nichols, MD, Gong Chen, PhD, Hua Zhong, PhD, William E. Pierceall, PhD, Jianguo Zhi, PhD, Lin-Chi Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 116.
https://doi.org/10.1182/blood.V124.21.116.116
Published: 2014